NEJM: A one-time inoculation stimulates a long-lasting negation antibody response, and Johnson and Johnson announces the latest early clinical results of the new crown vaccine

Ad26.COV2.S, a candidate vaccine developed by Johnson and Johnson, is one of the few vaccines scheduled to be vaccinated against COVID-19 through a one-time vaccination.
the latest results of the vaccine in a Phase 1/2a clinical trial were published in the New England Journal of Medicine.
test results showed that after a dose of Ad26.COV2.S vaccine, the vast majority of subjects produced a meso-antibody against the new coronavirus after vaccination, and antibody levels remained stable 71 days after vaccination.
Ad26.COV2.S uses the adenovirus vector Ad26 to express the full-length tingling protein of the new coronary protein.
animal tests showed that the vaccine was almost completely protective at once.
advantage of this vaccine in the study is that it can be preserved for a long time at -4 degrees C and maintain stability for 3 months at 2-8 degrees C.
, if a one-time inoculation produces good protection against COVID-19, it will lead to an easy-to-use vaccine option.
the first vaccination to stimulate a lasting antibody immune response in this trial, adult volunteers aged 18-55 and older volunteers over 65 were given different doses of Ad26.COV2.S or placebo, respectively.
test results showed that 99% and 96% of participants in the adult group who received low-dose/high-dose vaccines showed positive levels of the antibody serum 29 days after the first vaccination.
and the moderate antibody titration remained stable during subsequent follow-up, not only did the moderate antibody titration remain stable 71 days after the first inoculation, but 100% of the inoculators achieved the moderate antibody serum conversion.
results show the durability of the antibody immune response stimulated by Ad26.COV2.S.
Ad26.COV2.S was effective in stimulating the immune response of the antibody in both adults and the elderly (Photo source: Source: Reference) Participants in the group over 65 years of age achieved 96% (low dose) and 88% (high dose) of mesoantr antibody serum conversion rates, respectively, 29 days after the first vaccination.
concern about the new crown vaccine based on adenovirus is whether the presence of astrine-based meso-antibodies in the body will affect the effectiveness of the vaccine.
researchers found no correlation between the baseline level of neutral antibodies against Ad26 before vaccination and the level of neutral antibodies against Ad26 produced after the first vaccination.
immune response inspired by the vaccine helps to improve protection, in addition to the immune system's T-cell response plays an important role in providing COVID-19 protection.
in this trial, the majority of participants (60-83 percent) developed a CD4-positive T-cell reaction that tended to Th1 15 days after the first inoculation, both in the adult and older groups.
Ad26.COV2.S stimulates a CD4-positive T-cell immune response to Th1 in both adults and older adults (Photo Source: Resources) In the adult group, 51%-60% of the participants also developed a CD8-positive T-cell response to the pyrethroid protein, an immune response that helps eliminate cells infected with the new coronavirus.
a relatively low percentage (24-36%) of older adults with CD8-positive T-cell reactions.
the discussion, the researchers noted that a strong CD4-positive Th1 immune response, combined with a CD8-positive T-cell response and antibody response, minimizes the theoretical risk of vaccine-related respiratory diseases.
, the Phase 3 clinical trial to test the vaccine's protective effectiveness is expected to have interim results from late January to early February.
. Paul Stoffels, chief scientific officer at Johnson and Johnson, said in an interview that the results further strengthen confidence that Ad26.COV2.S is performing well in Phase 3 clinical trials.